JIC
OREX

Joel Isaacson & Co’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Joel Isaacson & Co’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-32
Closed -$2K – 650
2014
Q2 		$2K Hold
32
– – ﹤0.01% 554
2014
Q1 		$2K Hold
32
– – ﹤0.01% 549
2013
Q4 		$2K Hold
32
– – ﹤0.01% 496
2013
Q3 		$2K Hold
32
– – ﹤0.01% 480
2013
Q2 		$2K Buy
+32
New +$1.97K ﹤0.01% 442

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Joel Isaacson & Co's OREX Position: Q3 2014 in Review

Joel Isaacson & Co sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2014, closing a stake of 32 shares — an estimated $2K sold.

Joel Isaacson & Co first reported a position in OREX in Q2 2013 and held it in 5 quarters. The position peaked at $2K in Q2 2014. 128 funds tracked by Wall St. Rank hold OREX as of Q3 2014.

  • Joel Isaacson & Co reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2014 after selling out during the quarter.
  • Joel Isaacson & Co sold 32 Orexigen Therapeutics, Inc. shares in Q3 2014, an estimated $2K.
  • Joel Isaacson & Co first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 5 quarters.
  • Joel Isaacson & Co's Orexigen Therapeutics, Inc. position peaked at $2K in Q2 2014.
  • 128 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2014.

Based on Joel Isaacson & Co's 13F filing for Q3 2014, filed 22 Oct 2014.